This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Basic design

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The following features should be considered when assessing the basic design of drugs trials:

  • choice of subjects - define criteria for entry, exclusion criteria. Age, sex, severity, other illness other drugs, etc
  • controls - no treatment, placebo, other drug prescribed. Defined criteria for entry, comparable groups which are matched, and proper randomisation
  • cross over trials - beware washing out period and nature of the illness
  • historical controls can only rarely be used - e.g. paracetamol and N-acetyl cysteine.
  • randomisation - eliminate bias; once allocated include in analysis even if the patient drops out - avoids bias of choice, i.e. intention to treat. Need external coordinator. Need a good mechanism for blind allocation
  • blindness - single - patient, double - patient and doctor. Difficulty - drug may be a giveaway, and may unblind the study
  • placebo should be ordinarily indistinguishable from the drug
  • number of centres - e.g. ISIS - huge numbers
  • prospective or retrospective

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.